A Phase 1b randomized, double-blind, placebo-controlled trial in adults with Parkinson's disease and motor fluctuations.- SER-252-1b
Latest Information Update: 04 Dec 2025
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms SER-252-1b
Most Recent Events
- 03 Nov 2025 According to a Serina Therapeutics media release, the USFDA has placed a clinical hold on the IND application for SER-252, requesting additional information related to a commonly used excipient in the formulation, unrelated to to the active drug substance or its proposed mechanism of action.
- 22 Oct 2025 New trial record
- 06 Oct 2025 According to a Serina Therapeutics media release, company announced the drawdown of the first $5 million tranche from its previously announced financing agreement, which provides up to $20 million in funding upon achievement of defined development milestones.